Offer **regular clinical review** for people with meningioma to assess changes in their physical, psychological, and cognitive wellbeing
Base follow-up decisions on residual tumour, life expectancy, patient preferences, previous treatments, available treatment options, and tumour grade
Consider the frequency of follow-up based on these factors, with more frequent reviews potentially allowing earlier detection of recurrent disease, though evidence for improved outcomes is limited
Use regular clinical review and imaging to monitor for recurrence or progression, with the schedule tailored to tumour grade and individual circumstances
Take into account the potential late effects of treatment, such as cognitive decline, stroke risk, and secondary tumours, and assess these risks during follow-up
Encourage lifestyle modifications and consider additional assessments (e.g., ophthalmological, audiological, endocrine) based on individual risk factors
(see table 6 for factors influencing follow-up frequency) NICE NG99